Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2017

Open Access 01-12-2017 | Research article

Cancer mortality in former East and West Germany: a story of unification?

Authors: Daniel Medenwald, Dirk Vordermark, Christian T. Dietzel

Published in: BMC Cancer | Issue 1/2017

Login to get access

Abstract

Background

Health and social conditions vary between West and East Germany.

Methods

We analyzed annual mortality data of all recorded deaths caused by lung, colorectal, breast and prostate cancer in Germany as they are published by the Federal Bureau of Statistics (FBS) encompassing the period 1980–2014 for former West Germany (WG) and 1990–2014 for former East Germany (EG). To compare East and West Germany we computed the ratio of the mortality rates in both parts (mortality rate ratio, MRR, <1 indicates a lower mortality in EG). Forecasting methods of time series analyses were applied (model selection based on the Box/Jenkins approach) to predict 5-year trends until 2019.

Results

Lung cancer: In women mortality rose in both regions (WG: +2.8%, 1991–2014, EG: +2.2%, 1990–2014). In men mortality in WG declined between −2.1% and −1.2%, and by −2.7% (1993–2009) in EG which was followed by a plateau. Colorectal cancer: A decline was found in both WG (−3.1%, 1993–2014) and EG women (−3.8%, 1993–2008 and −2.0%, 2008–2014). A decline in EG men since 1992 (−0.9%, 1992–1997 and −2.3%, 1997–2014) mirrors the development in WG (−2.6%, 1995–2014). Breast cancer: Constant mortality decline in WG after 1996. In EG a decline (−2.4%, 1992–2007) was followed by a plateau with an MRR <1 (1990–2014). Prostate cancer: In WG a decline (−3.4%) came to a hold after 2007, while there was a constant decline of 1.5% in EG. The forecast indicated that mortality of colorectal/lung cancer in men and breast cancer reaches a plateau in future years.

Conclusion

Courses of mortality were similar between East and West, while existing differences are likely to remain in the near future.
Appendix
Available only for authorised users
Literature
1.
Bosetti C, Bertuccio P, Malvezzi M, Levi F, Chatenoud L, Negri E, La Vecchia C. Cancer mortality in Europe, 2005–2009, and an overview of trends since 1980. Ann Oncol. 2013;24(10):2657–71.CrossRefPubMed
2.
Baili P, Di Salvo F, Marcos-Gragera R, Siesling S, Mallone S, Santaquilani M, Micheli A, Lillini R, Francisci S, Group E-W: Age and case mix-standardised survival for all cancer patients in Europe 1999–2007: Results of EUROCARE-5, a population-based study. Eur J Cancer. 2015;51(15):2120–2129.
3.
Quaglia A, Lillini R, Mamo C, Ivaldi E, Vercelli M, SEIH (Socio-Economic Indicators HaWG. Socio-economic inequalities: a review of methodological issues and the relationships with cancer survival. Crit Rev Oncol Hematol. 2013;85(3):266–77.CrossRefPubMed
4.
Lillini R, Vercelli M, Quaglia A, Micheli A, Capocaccia R. Use of socio-economic factors and healthcare resources to estimate cancer survival in European countries with partial national cancer registration. Tumori. 2011;97(3):265–74.PubMed
5.
Jansen L, Gondos A, Eberle A, Emrich K, Holleczek B, Katalinic A, Brenner H, Group GCSW. Cancer survival in Eastern and Western Germany after the fall of the iron curtain. Eur J Epidemiol. 2012;27(9):689–93.CrossRefPubMed
6.
7.
Box GEP, Jenkins GM. Time series analysis: forecasting and control. San Francisco: Holden-Day; 1976.
8.
Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000;19(3):335–51.CrossRefPubMed
9.
Team RC. A Language and Environment for Statistical Computing. Vienna: R Foundation for Statistical Computing; 2014.
10.
Kibele EUB: Regional mortality differences in Germany. In. Dordrecht: Demographic Research Monographs, Springer; 2012. pp. 14–22.
11.
Luy M: Mortality differences between Western and Eastern Germany before and after Reunification A macro and micro level analysis of developments and responsible factors. Genus. 2004;60(3/4):99–141.
12.
Nolte E, Shkolnikov V, McKee M. Changing mortality patterns in East and West Germany and Poland. II: short-term trends during transition and in the 1990s. J Epidemiol Community Health. 2000;54(12):899–906.CrossRefPubMedPubMedCentral
13.
Islami F, Torre LA, Jemal A. Global trends of lung cancer mortality and smoking prevalence. Transl Lung Cancer Res. 2015;4(4):327–38.PubMedPubMedCentral
14.
John U, Hanke M. Lung cancer mortality and years of potential life lost among males and females over six decades in a country with high smoking prevalence: an observational study. BMC Cancer. 2015;15:876.CrossRefPubMedPubMedCentral
15.
Myrskylä M, Scholz R. Reversing East–west mortality difference among German women, and the role of smoking. Int J Epidemiol. 2013;42(2):549–58.CrossRefPubMed
16.
Malvezzi M, Bertuccio P, Rosso T, Rota M, Levi F, La Vecchia C, Negri E. European cancer mortality predictions for the year 2015: does lung cancer have the highest death rate in EU women? Ann Oncol. 2015;26(4):779–86.CrossRefPubMed
17.
Bosetti C, Levi F, Rosato V, Bertuccio P, Lucchini F, Negri E, La Vecchia C. Recent trends in colorectal cancer mortality in Europe. Int J Cancer. 2011;129(1):180–91.CrossRefPubMed
18.
Hamza S, Cottet V, Touillon N, Dancourt V, Bonithon-Kopp C, Lepage C, Faivre J. Long-term effect of faecal occult blood screening on incidence and mortality from colorectal cancer. Dig Liver Dis. 2014;46(12):1121–5.CrossRefPubMed
19.
Brenner H, Altenhofen L, Kretschmann J, Rösch T, Pox C, Stock C, Hoffmeister M. Trends in Adenoma Detection Rates During the First 10 Years of the German Screening Colonoscopy Program. Gastroenterology. 2015;149(2):e351–366.CrossRef
20.
de Leon MP, Pezzi A, Benatti P, Manenti A, Rossi G, di Gregorio C, Roncucci L. Survival, surgical management and perioperative mortality of colorectal cancer in the 21-year experience of a specialised registry. Int J Colorectal Dis. 2009;24(7):777–88.CrossRefPubMed
21.
Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351(17):1731–40.CrossRefPubMed
22.
Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C, Becker H, Raab HR, Villanueva MT, Witzigmann H, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012;30(16):1926–33.CrossRefPubMed
23.
Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med. 2005;352(5):476–87.CrossRefPubMed
24.
25.
Mensink GB, Beitz R. Food and nutrient intake in East and West Germany, 8 years after the reunification--The German Nutrition Survey 1998. Eur J Clin Nutr. 2004;58(7):1000–10.CrossRefPubMed
26.
Germany (West). Bundesminister fur Jugend FuG. Indikatoren zum Gesundheitszustand der Bevolkerung in der ehemaligen DDR Herausgeber: Der Bundesminister fur Gesundheit, vol. Bd. 23. Baden-Baden: Nomos Verlagsgesellschaft; 1993.
27.
Kaplan HG, Malmgren JA, Atwood MK, Calip GS. Effect of treatment and mammography detection on breast cancer survival over time: 1990–2007. Cancer. 2015;121(15):2553–61.CrossRefPubMed
28.
Agarwal S, Pappas L, Neumayer L, Kokeny K, Agarwal J. Effect of breast conservation therapy vs mastectomy on disease-specific survival for early-stage breast cancer. JAMA Surg. 2014;149(3):267–74.CrossRefPubMed
29.
McGale P, Taylor C, Correa C, Cutter D, Duane F, Ewertz M, Gray R, Mannu G, Peto R, Whelan T, et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet. 2014;383(9935):2127–35.CrossRefPubMed
30.
Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, Cutter D, Davies C, Ewertz M, Godwin J, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378(9804):1707–16.CrossRefPubMed
31.
Njor S, Nyström L, Moss S, Paci E, Broeders M, Segnan N, Lynge E, Group EW. Breast cancer mortality in mammographic screening in Europe: a review of incidence-based mortality studies. J Med Screen. 2012;19 Suppl 1:33–41.CrossRefPubMed
32.
Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–33.CrossRefPubMed
33.
Katalinic A, Lemmer A, Zawinell A, Rawal R, Waldmann A. Trends in hormone therapy and breast cancer incidence - results from the German Network of Cancer Registries. Pathobiology. 2009;76(2):90–7.CrossRefPubMed
34.
Katalinic A, Pritzkuleit R, Waldmann A. Recent Trends in Breast Cancer Incidence and Mortality in Germany. Breast Care (Basel). 2009;4(2):75–80.CrossRef
35.
36.
Britt K, Ashworth A, Smalley M. Pregnancy and the risk of breast cancer. Endocr Relat Cancer. 2007;14(4):907–33.CrossRefPubMed
37.
Ursin G, Bernstein L, Lord SJ, Karim R, Deapen D, Press MF, Daling JR, Norman SA, Liff JM, Marchbanks PA, et al. Reproductive factors and subtypes of breast cancer defined by hormone receptor and histology. Br J Cancer. 2005;93(3):364–71.CrossRefPubMedPubMedCentral
38.
Kreyenfeld M: Crisis or Adaptation – Reconsidered: A Comparison of East and West German Fertility Patterns in the First Six Years after the ‘Wende'. European Journal of Population / Revue européenne de Démographie. 2003;19(3):303–329.
39.
40.
Dörr M, Hölzel D, Schubert-Fritschle G, Engel J, Schlesinger-Raab A. Changes in prognostic and therapeutic parameters in prostate cancer from an epidemiological view over 20 years. Oncol Res Treat. 2015;38(1–2):8–14.CrossRefPubMed
Metadata
Title
Cancer mortality in former East and West Germany: a story of unification?
Authors
Daniel Medenwald
Dirk Vordermark
Christian T. Dietzel
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2017
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-017-3086-y

Other articles of this Issue 1/2017

BMC Cancer 1/2017 Go to the issue

Research article

The miR-34a-5p promotes the multi-chemoresistance of osteosarcoma via repression of the AGTR1 gene

Research article

Interval breast cancer characteristics before, during and after the transition from screen-film to full-field digital screening mammography

Research article

ERp29 controls invasion and metastasis of gastric carcinoma by inhibition of epithelial-mesenchymal transition via PI3K/Aktsignaling pathway

Research article

High expression of micro RNA-135A in hepatocellular carcinoma is associated with recurrence within 12 months after resection

Research article

Identifying global expression patterns and key regulators in epithelial to mesenchymal transition through multi-study integration

Erratum

Erratum to: gamma probe and ultrasound guided fine needle aspiration cytology of the sentinel node (GULF) trial - overview of the literature, pilot and study protocol
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits